Demonstration of a Common DPhe<sup>7</sup> to DNal(2′)<sup>7</sup> Peptide Ligand Antagonist Switch for Melanocortin-3 and Melanocortin-4 Receptors Identifies the Systematic Mischaracterization of the Pharmacological Properties of Melanocortin Peptides-Reference-Cited by-同舟云学术

Demonstration of a Common DPhe⁷ to DNal(2′)⁷ Peptide Ligand Antagonist Switch for Melanocortin-3 and Melanocortin-4 Receptors Identifies the Systematic Mischaracterization of the Pharmacological Properties of Melanocortin Peptides

Published:2022-04-11 Issue:8 Volume:65 Page:5990-6000
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Gimenez Luis E.¹,Noblin Terry A.¹,Williams Savannah Y.¹,Mullick Bagchi Satarupa¹,Ji Ren-Lei²,Tao Ya-Xiong²^ORCID,Jeppesen Claus B.³,Conde-Frieboes Kilian W.⁴^ORCID,Sawyer Tomi K.⁵,Grieco Paolo,Cone Roger D.¹⁶^ORCID

Affiliation:

1. Life Sciences Institute, University of Michigan, Ann Arbor, Michigan 48109, United States

2. Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, Alabama 36849, United States

3. Global Drug Discovery, Novo Nordisk A/S, 2760 Måløv, Denmark

4. Global Research Technology, Novo Nordisk A/S, 2760 Måløv, Denmark

5. Courage Therapeutics, 64 Homer Street, Newton, Massachusetts 02459, United States

6. Department of Molecular and Integrative Physiology, School of Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States

Funder

National Institute of Diabetes and Digestive and Kidney Diseases

Klarman Family Foundation

National Institute of Nursing Research

Courage Therapeutics, Inc.